幽门螺杆菌诱发癌症的最佳预防现状
Current Understanding of Optimal Prevention of Helicobacter pylori-Induced Cancer.
作者信息
Oje Adesola, Galati Jonathan, Peek Richard M
机构信息
Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, TN, USA.
Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, TN, USA.
出版信息
Gastroenterol Clin North Am. 2025 Jun;54(2):397-413. doi: 10.1016/j.gtc.2024.12.005. Epub 2025 Jan 24.
Abstract
Gastric cancer is the fifth most common cancer and the fifth most common cause of cancer-related death globally. The key to improving outcomes lies in effective prevention and early detection, which are critical for successful curative interventions. Helicobacter pylori is the strongest known risk factor for gastric cancer, and eradication of this pathogen is critical for reducing cancer risk. By synthesizing current evidence and exploring the advanced therapeutic approaches, this review provides a comprehensive overview of best practices for mitigating gastric cancer through targeted bacterial intervention.
摘要
胃癌是全球第五大常见癌症，也是癌症相关死亡的第五大常见原因。改善治疗效果的关键在于有效的预防和早期检测，这对于成功的治愈性干预至关重要。幽门螺杆菌是已知最强的胃癌风险因素，根除这种病原体对于降低癌症风险至关重要。通过综合当前证据并探索先进的治疗方法，本综述全面概述了通过针对性细菌干预减轻胃癌的最佳实践。
相似文献
1
Current Understanding of Optimal Prevention of Helicobacter pylori-Induced Cancer.幽门螺杆菌诱发癌症的最佳预防现状
Gastroenterol Clin North Am. 2025 Jun;54(2):397-413. doi: 10.1016/j.gtc.2024.12.005. Epub 2025 Jan 24.
2
Helicobacter pylori eradication for the prevention of gastric neoplasia.根除幽门螺杆菌以预防胃部肿瘤
Cochrane Database Syst Rev. 2015 Jul 22;2015(7):CD005583. doi: 10.1002/14651858.CD005583.pub2.
3
The Cost-Effectiveness of Adding Helicobacter Pylori Screening to the National Gastric Cancer Screening Program in Korea: Protocol for a Cost-Effectiveness Modeling Study.在韩国国家胃癌筛查项目中增加幽门螺杆菌筛查的成本效益：成本效益建模研究方案
JMIR Res Protoc. 2025 Jul 15;14:e72228. doi: 10.2196/72228.
4
Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer.系统评价：根除幽门螺杆菌预防胃癌
Aliment Pharmacol Ther. 2007 Jan 15;25(2):133-41. doi: 10.1111/j.1365-2036.2006.03183.x.
5
Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis.幽门螺杆菌根除与胃癌发病率的关系：系统评价和荟萃分析。
Gastroenterology. 2016 May;150(5):1113-1124.e5. doi: 10.1053/j.gastro.2016.01.028. Epub 2016 Feb 2.
6
Gastric cancer risk after Helicobacter pylori eradication in gastritis and peptic ulcer: a retrospective cohort study in Japan.胃炎和消化性溃疡患者根除幽门螺杆菌后的胃癌风险：日本的一项回顾性队列研究
BMC Gastroenterol. 2025 Jul 1;25(1):463. doi: 10.1186/s12876-025-04034-3.
7
Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people.幽门螺杆菌阳性人群消化性溃疡疾病的根除治疗。
Cochrane Database Syst Rev. 2016 Apr 19;4(4):CD003840. doi: 10.1002/14651858.CD003840.pub5.
8
Helicobacter pylori eradication and gastric cancer prevention in a pooled analysis of large-scale cohort studies in Japan.日本大规模队列研究的汇总分析中幽门螺杆菌根除与胃癌预防
Sci Rep. 2025 Jul 1;15(1):21307. doi: 10.1038/s41598-025-00713-z.
9
The management of Helicobacter pylori infection in primary care: a systematic review of the literature.基层医疗中幽门螺杆菌感染的管理：文献系统评价
Fam Pract. 2000 Aug;17 Suppl 2:S6-11. doi: 10.1093/fampra/17.suppl_2.s6.
10
[INFLUENCE OF DIET IN PRIMARY PREVENTION OF GASTRIC CANCER, IN PATIENTS INFECTED WITH HELICOBACTER PYLORI].[饮食对幽门螺杆菌感染患者胃癌一级预防的影响]
Rev Enferm. 2016 May;39(5):33-8.
本文引用的文献
1
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.美国胃肠病学会临床指南：幽门螺杆菌感染的治疗
Am J Gastroenterol. 2024 Sep 1;119(9):1730-1753. doi: 10.14309/ajg.0000000000002968. Epub 2024 Sep 4.
2
Differences in cancer rates among adults born between 1920 and 1990 in the USA: an analysis of population-based cancer registry data.美国 1920 年至 1990 年出生的成年人中癌症发病率的差异：基于人群的癌症登记数据分析。
Lancet Public Health. 2024 Aug;9(8):e583-e593. doi: 10.1016/S2468-2667(24)00156-7.
3
Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries.四联疗法在 LEGACy 联盟中与标准三联疗法相比，对幽门螺杆菌感染的根除率更高。一项在欧洲和拉丁美洲国家进行的多中心观察性研究。
United European Gastroenterol J. 2024 Nov;12(9):1190-1199. doi: 10.1002/ueg2.12605. Epub 2024 Aug 1.
4
Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.社区消除幽门螺杆菌预防胃癌：一项整群随机对照试验。
Nat Med. 2024 Nov;30(11):3250-3260. doi: 10.1038/s41591-024-03153-w. Epub 2024 Jul 30.
5
Real-world efficacy of second-line therapies for Helicobacter pylori: a population-based study.基于人群的研究：二线疗法治疗幽门螺杆菌的真实世界疗效。
J Antimicrob Chemother. 2024 Sep 3;79(9):2263-2272. doi: 10.1093/jac/dkae224.
6
Epidemiology of Gastric Cancer: Global Trends, Risk Factors and Premalignant Conditions.胃癌流行病学：全球趋势、危险因素及癌前病变
J Community Hosp Intern Med Perspect. 2023 Nov 4;13(6):100-106. doi: 10.55729/2000-9666.1252. eCollection 2023.
7
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
8
Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy.基于 vonoprazan 的三联疗法与铋四联疗法根除幽门螺杆菌的疗效的荟萃分析。
Helicobacter. 2024 Mar-Apr;29(2):e13059. doi: 10.1111/hel.13059.
9
Prevalence of Gastric Precursor Lesions in Countries With Differential Gastric Cancer Burden: A Systematic Review and Meta-analysis.不同胃癌负担国家胃前病变的流行情况：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2024 Aug;22(8):1605-1617.e46. doi: 10.1016/j.cgh.2024.02.023. Epub 2024 Mar 2.
10
Sequential versus Standard Triple Therapy for First-Line Eradication: An Update.一线根除治疗的序贯疗法与标准三联疗法：最新进展
Antibiotics (Basel). 2024 Jan 30;13(2):136. doi: 10.3390/antibiotics13020136.
Zotero 插件